Colon capsule endoscopy leading to gastrointestinal stromal tumor (GIST) diagnosis after colonoscopy failure by unknown
Stemate et al. BMC Res Notes  (2015) 8:558 
DOI 10.1186/s13104-015-1444-x
CASE REPORT
Colon capsule endoscopy leading 
to gastrointestinal stromal tumor (GIST) 
diagnosis after colonoscopy failure
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Abstract 
Background: Gastrointestinal stromal tumors are a subtype of mesenchymal tumors. In recent years a significant 
progress was made in their diagnosis and treatment which led to significant improvement of their prognosis. Endos-
copy remains one of the main diagnostic methods. In the rare instance of colonoscopy failure, different approaches 
are available: different endoscope, computed tomography colonography, capsule endoscopy, use of an enteroscope.
Case presentation: We present the case of a 75-year-old Caucasian man admitted for abdominal pain, diarrhea and 
weight loss. Two colonoscopy attempts failed in a different center and a decision to use colon capsule endoscopy was 
made. This exam revealed a submucosal mass located in the sigmoid colon. Surgery was performed and a local invad-
ing gastrointestinal stromal tumor was removed. This is the first image of a colonic gastrointestinal stromal tumor 
seen on capsule endoscopy.
Conclusion: Colon capsule is a useful diagnostic tool in selected patients after colonoscopy failure or 
contraindication.
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Background
Gastrointestinal stromal tumors are a subtype of mes-
enchymal tumors. Even if they represent only 1 % of the 
digestive tumors, they had reached celebrity in the last 
years, due to better understanding of their pathogen-
esis and progress in their diagnosis due to the new and 
improved imaging tools. Also, a significant progress was 
made with a targeted molecular treatment which led to 
significant improvement of their prognosis.
The most common locations of GIST’s are the stom-
ach (50–60  %) and small intestine (30–40  %) and only 
less then 5–10  % develops in colon, rectum and 1  % in 
esophagus [1, 2]. Similar tumors may arise in omentum, 
mesentery, retroperitoneum, pancreas, liver, gallbladder 
and urinary bladder. These tumors are called extragastro-
intestinal stromal tumors (EGISTs) [3, 4].
Endoscopy, echoendoscopy and computed tomogra-
phy scan are the mean diagnostic methods. We present 
the case of a patient with a sigmoid colon located GIST, 
where diagnosis was established using capsule endoscopy 
after a failed colonoscopy examination.
Case presentation
A 75-year-old Caucasian man presented to our depart-
ment with recurrent left lower quadrant abdominal pain, 
weight loss and progressive asthenia. The stools were 
occasional diarrheic, with no visible blood. The symp-
toms started a few months earlier and they gradually 
increased. He had no significant medical history.
The clinical examination showed a pale patient, with 
left lower abdominal quadrant pain, no palpable masses, 
no ascites and no peripheral edema. The blood tests were 
within normal limits except mild iron deficiency anemia 
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(hemoglobin 10.2  g/dl, serum iron 33  μg/dl) and an 
inflammatory syndrome (positive C—reactive protein, 
high erythrocyte sedimentation rate 42 mm/h).
The patient had been admitted in a different depart-
ment in the previous month, where an upper endoscopy 
that found no lesions and two colonoscopies attempts 
which failed to pass the sigmoid colon were performed. 
He underwent a barium enema and he was diagnosed 
with diverticulosis. His symptoms were interpreted as a 
diverticulitis attack. He received anti-diarrheics, spasmo-
lytics, and a fluoroquinolone with partial and temporary 
symptom alleviation.
He was referred to our unit for a second opinion. Since he 
had two failures of colonoscopy and since we had an ongoing 
study using the Pillcam Colon2 videocapsule for the patients 
unable or unwilling to undergo colonoscopy, we decided to 
use the Pillcam Colon2 videocapsule from Given Imaging for 
the colonic exploration. The use of colon capsule endoscopy 
was not standard care at our institute at that time, but we 
considered it was the best alternative for our patient. Lately, 
according to the current European Society of Gastrointesti-
nal Endoscopy capsule endoscopy guidelines, CCE is feasible 
and safe for visualization of colonic mucosa in patients with 
incomplete colonoscopy and without stenosis. [8].
After review of his barium irigography, no colonic ste-
nosis was suspected. A complete colonic examination 
was obtained by capsule and showed multiple diver-
ticula with no signs of inflammation of the surround-
ing mucosa. However, we noticed a submucosal mass 
approximately 3  cm in diameter located in the sigmoid 
colon Fig. 1.
A CT scan of the abdomen and the pelvis showed multi-
ple colonic diverticula and a soft tissue mass of 5 cm diam-
eter with a necrotic centre, with increased thickness of the 
sigmoid wall. No clear demarcation between the mass and 
the urinary bladder was visible and important densifica-
tion of the perisigmoidian fat was also noticed. Although 
a peridiverticular abscess was possible, viewing the CT 
aspect corroborated with the capsule images, the diagnosis 
of a tumor with necrotizing center, probably a GIST it was 
more likely, as this kind of necrosis is quite specific and 
previously described in GIST’s [5]. The patient underwent 
surgery with complete tumor resection. The lymph nodes 
examined during surgery were not involved.
The histopathological examination report revealed a 
sigmoid GIST with a tumor size more than 5  cm, with 
spindle cells, CD117 positive and a mitotic rate more 
than 5/50 HPF and since the patient had no signifi-
cant comorbidities we considered him for the adjuvant 
therapy. The patient started treatment with imatinib 
mesylate, with good evolution at 6 months.
Discussion
The clinical features of GIST’s are variable, related to 
the presence of mass, perforation or obstruction. The 
presentation can be with abdominal pain or discomfort, 
acute or chronic bleeding or anorexia [1]. Some patients 
remain asymptomatic and some GISTs are detected by 
random imagistic examinations or at autopsy.
Specific morphological and immunohistochemical fea-
tures establish the definite diagnosis of GIST: they are 
formed by spindle or epithelioid cells which are express-
ing CD117 and mutations in KIT or PDGFRα (platelet 
derived growth factor alpha). Approximately 80  % also 
express CD34. Less then 5 % are c-KIT negative [6].
Endoscopy is one of the main methods of diagnosis. 
Although the rate of colonoscopy completeness is as high 
as 97 % in expert centers, a variable proportion (4–20 %) 
of patients will have an incomplete colonoscopy [7].
After an incomplete colonoscopic examination different 
approaches can be tried: variable stiffness colonoscope, 
use of gastroscope, single or double balloon enteroscopy 
(not readily available in all centers). Changing the cen-
tre or the endoscopist is an alternative. However, a first 
failed colonoscopy is more commonly associated with 
a lower future success rate, particularly when stopped 
in the sigmoid [7]. Radiological methods as double con-
trast barium enema or CT colonography are also useful 
examination tools. Lately, colon capsule endoscopy was 
regarded as a possible alternative for such patients. The 
current European Society of Gastrointestinal Endoscopy 
capsule endoscopy guideline takes into consideration 
the utilization of CCE after failure or refuse of colonos-
copy. According to these guidelines, CCE is feasible and Fig. 1 Ulcerated submucosal mass in the sigmoid colon
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safe and appears to be accurate when used in average-risk 
individuals and in high risk patients for whom colonos-
copy is inappropriate or not possible. For these patients 
the use of CCE could be an alternative [8].
At the moment four studies address this issue, three 
using the first generation colon capsule, the other, from 
our center, presenting the results of the second genera-
tion colon capsule. All studies conclude that colon capsule 
endoscopy can be very useful in the setting of selected 
patients after colonoscopy failure or contraindication 
[9–12]. In this particular case the colon capsule permitted 
the visualization of a mass in sigmoid (not seen in barium 
contrast enema) and played a crucial role in the differential 
diagnosis with diverticulitis. All GIST’s have a malignant 
potential with metastases being detected at the moment of 
diagnosis in 50 % of cases. The common metastatic sites of 
GIST’s are the liver and the peritoneum with rare lymph 
node involvement occurring in only 0–8  % of cases. The 
prognosis depends on the site and size of the tumor and 
mitotic rate. Small tumors (<2 cm) and mitotic activity of 
less then 5 mitoses per 50 HPFs have an excellent progno-
sis, probably independent of site. The Ki67 index may help 
identify tumors with malignant potential [13].
Complete surgical resection is the treatment of choice 
for GIST’s [14]. Imatinib mesylate is a synthetic tyrosine 
kinase inhibitor and is considered the drug of choice for 
metastatic and inoperable GISTs [15]. Also, from 2008, 
the FDA approved imatinib mesylate for the adjuvant 
therapy of primary resected GIST [16].
Conclusion
The colonic GIST’s are rare and a proper evaluation, 
diagnosis and treatment are needed for the best outcome. 
In the instance of failing colonoscopy, a useful alternative 
is colon capsule endoscopy.
This is the first case to our knowledge, presenting the 
capsule image of a colonic GIST. In our patient the cap-
sule endoscopy made the difference, making the correct 
diagnosis possible and permitting a specific treatment.
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